Risk factors for Alzheimer's disease and related dementia: A lifecourse approach

被引:2
作者
Singh-Manoux, A. [1 ,2 ]
Sabia, S. [1 ,2 ]
机构
[1] Univ Paris, Epidemiol Ageing & Neurodegenerat Dis, Inserm U1153, F-75010 Paris, France
[2] Univ Paris, Inserm U1153, 10 Ave Verdun, F-75010 Paris, France
来源
BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE | 2020年 / 204卷 / 03期
关键词
Neurodegenerative; Diseases; Alzheimer Disease; Risk factors; COGNITIVE DECLINE; PHYSICAL-ACTIVITY; NEUROPATHOLOGY; PREVENTION; AGE;
D O I
10.1016/j.banm.2020.01.015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Alzheimer's disease and related dementias are devastating for the individual and their entourage, they also carry tremendous financial burden for society at large. Age is the principal risk factor, with the risk doubling every 5 years after the age of 65 years. Research has clearly established that pathophysiological changes occur ten to fifteen years before the diagnosis of disease. This has implications for understanding risk and protective factors of the disease as most longitudinal studies were set up in adults over 65 years of age at the start of the study and the follow-up for incidence of Alzheimer's disease is often less than ten years. Thus, the results from such studies are likely to be biased by reverse causation. This has led to inconsistent findings in studies and a varying list of risk and protective factors produced by various guidelines published in recent years. In this paper, we describe these challenges and propose the use of a lifecourse approach for the identification of risk and protective factors. We also highlight the need to extend research on biomarkers to peripheral biomarkers; proteomics, in particular, as they reflect both genetic and environmental effects and are potentially modifiable. (C) 2020 l'Academie nationale de medecine. Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:217 / 223
页数:7
相关论文
共 45 条
  • [1] Association between systolic blood pressure and dementia in the Whitehall II cohort study: role of age, duration, and threshold used to define hypertension
    Abell, Jessica G.
    Kivimaki, Mika
    Dugravot, Aline
    Tabak, Adam G.
    Fayosse, Aurore
    Shipley, Martin
    Sabia, Severine
    Singh-Manoux, Archana
    [J]. EUROPEAN HEART JOURNAL, 2018, 39 (33) : 3119 - 3125
  • [2] Alzheimer's Association, 2016, Alzheimers Dement, V12, P459
  • [3] BARNES DE, 2011, LANCET NEUROL
  • [4] Neuropathology of older persons without cognitive impairment from two community-based studies
    Bennett, D. A.
    Schneider, J. A.
    Arvanitakis, Z.
    Kelly, J. F.
    Aggarwal, N. T.
    Shah, R. C.
    Wilson, R. S.
    [J]. NEUROLOGY, 2006, 66 (12) : 1837 - 1844
  • [5] Physical Activity Interventions in Preventing Cognitive Decline and Alzheimer-Type Dementia A Systematic Review
    Brasure, Michelle
    Desai, Priyanka
    Davila, Heather
    Nelson, Victoria A.
    Calvert, Collin
    Jutkowitz, Eric
    Butler, Mary
    Fink, Howard A.
    Ratner, Edward
    Hemmy, Laura S.
    McCarten, J. Riley
    Barclay, Terry R.
    Kane, Robert L.
    [J]. ANNALS OF INTERNAL MEDICINE, 2018, 168 (01) : 30 - +
  • [6] Dementia and aging populations-A global priority for contextualized research and health policy
    Brayne, Carol
    Miller, Bruce
    [J]. PLOS MEDICINE, 2017, 14 (03)
  • [7] Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease
    Brookmeyer, Ron
    Abdalla, Nada
    [J]. ALZHEIMERS & DEMENTIA, 2018, 14 (08) : 981 - 988
  • [8] Deep undepleted human serum proteome profiling toward biomarker discovery for Alzheimer's disease
    Dey, Kaushik Kumar
    Wang, Hong
    Niu, Mingming
    Bai, Bing
    Wang, Xusheng
    Li, Yuxin
    Cho, Ji-Hoon
    Tan, Haiyan
    Mishra, Ashutosh
    High, Anthony A.
    Chen, Ping-Chung
    Wu, Zhiping
    Beach, Thomas G.
    Peng, Junmin
    [J]. CLINICAL PROTEOMICS, 2019, 16 (1)
  • [9] Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment
    Dotson, Vonetta M.
    Beydoun, May A.
    Zonderman, Alan B.
    [J]. NEUROLOGY, 2010, 75 (01) : 27 - 34
  • [10] Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease
    Egan, Michael F.
    Kost, James
    Tariot, Pierre N.
    Aisen, Paul S.
    Cummings, Jeffrey L.
    Vellas, Bruno
    Sur, Cyrille
    Mukai, Yuki
    Voss, Tiffini
    Furtek, Christine
    Mahoney, Erin
    Mozley, Lyn Harper
    Vandenberghe, Rik
    Mo, Yi
    Michelson, David
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (18) : 1691 - 1703